脐带间充质干细胞移植治疗终末期肝硬化的疗效及安全性

背景：骨髓间充质干细胞移植已应用于治疗终末期肝病并取得一定疗效。目的：观察脐带间充质干细胞治疗终末期肝硬化患者的疗效及安全性。方法：无菌条件下分离培养脐带间充质干细胞,选择60例肝硬化患者,在内科治疗基础上经肝动脉插管进行脐带间充质干细胞移植。结果与结论：移植2,4,8,12周后,患者血清白蛋白、前白蛋白水平逐渐升高(P < 0.05),总胆红素、凝血酶原时间明显低于治疗前水平(P < 0.05)。移植后患者乏力、腹胀、纳差明显好转,未发生与移植相关的严重并发症。说明脐带间充质干细胞治疗终末期肝硬化安全有效,能改善患者的肝功能、凝血功能及临床症状。

Effect and safety of umbilical cord mesenchymal stem cells transplantation on end-stage liver cirrhosis

BACKGROUND:Bone mesenchymal stem cells (BMSCs) transplantation has been used for end-stage liver cirrhosis, and obtained some results.OBJECTIVE:To observe the effect and safety of umbilical cord mesenchymal stem cells (UCMSCs) transplantation on end-stage hepatic cirrhosis.METHODS:UCMSCs were isolated under sterile conditions. Sixty cases of liver cirrhosis received basic medication and UCMSCs transplantation by way of hepatic artery. RESULTS AND CONCLUSION: After UCMSCs treatment, the level of albumin, prealbumin and fibrinogen were significantly increased (P < 0.05), and the levels of total bilirubin and prothrombin time were obviously reduced (P < 0.05). The symptoms such as fatigue, abdominal distension, anorexia relieved after treatment. UCMSCs transplantation for end-stage liver cirrhosis is safe and effective, and it can improve patients’ liver function, blood clotting and relieve clinical symptoms.